Next Article in Journal
Optimization, Characterisation and Pharmacokinetic Studies of Mucoadhesive Oral Multiple Unit Systems of Ornidazole
Previous Article in Journal
Phenolics from Rhagadiolus stellatus (Asteraceae, Cichorieae)
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2015). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessShort Communication
Sci. Pharm. 2014, 82(1), 21-28; https://doi.org/10.3797/scipharm.1307-25 (registering DOI)

Biological Evaluation of Isoniazid Derivatives as an Anticancer Class

1
Laboratório de Oncologia Experimental, Universidade Federal do Ceará, Fortaleza, CE, Brazil
2
FioCruz-Fundação Oswaldo Cruz, Instituto de Tecnologia em Fármacos-Far-Manguinhos, Rua Sizenando Nabuco, 100, Manguinhos, 21041-250 Rio de Janeiro, RJ, Brazil
*
Author to whom correspondence should be addressed.
Received: 31 July 2013 / Accepted: 22 September 2013 / Published: 22 September 2013
Download PDF [121 KB, uploaded 26 September 2016]

Abstract

A series of thirty-two isoniazid derivatives have been evaluated for their activity against four human cancer cell lines with potent cytotoxicity (IC50 ranging from 0.61 to 3.36 μg/mL). The structure-activity relationship (SAR) analysis indicated the number, the positions, and the types of substituents attached to the aromatic ring as being critical factors for the biological activity. Briefly, we observed that the presence of a hydroxyl group on the benzene ring plays an important role in the anticancer activity of this series, especially when it is located in ortho-position. Among the thirty-two compounds, three displayed good cytotoxic activity when compared to the reference drug doxorubicin and are thus being considered leading compounds of this new class.
Keywords: Antitumor activity; Isoniazid; Hydrazone; Drugs; Cytotoxicity Antitumor activity; Isoniazid; Hydrazone; Drugs; Cytotoxicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

RODRIGUES, F.A.R.; OLIVEIRA, A.C.A.; CAVALCANTI, B.C.; PESSOA, C.; PINHEIRO, A.C.; DE SOUZA, M.V.N. Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Sci. Pharm. 2014, 82, 21-28.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top